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β-carbolinesHarmicine is a β-carboline alkaloid isolated and identiﬁed as a major active compound present in many plant
species and marine invertebrates. This alkaloid exhibits a wide spectrum of pharmacological activities, in-
cluding antispasmodic, antipyretic, and anticancer properties. This report described the antinociceptive prop-
erties of harmicine by means of chemical experimental models in order to evaluate the use for pain relief. The
results demonstrating the potential analgesic properties of harmicine administered intraperitoneally were
shown with the writhing test, reducing writhes around 60% (1 mg/kg), and in the formalin test, where har-
micine was more effective toward neurogenic (reducing reaction time around 60%, 1 mg/kg) than inﬂamma-
tory (68% reduction, 10 mg/kg) pain responses. Furthermore, these effects may operate via vanilloid
receptors as revealed by the capsaicin test (41% reduction, with 3 mg/kg), as well as via peripheral glutamate
receptors as shown by the glutamate test (50% reduction, with 1 mg/kg). Moreover, the opioid antagonist
naloxone hydrochloride did not interfere in the antinociceptive properties of harmicine in the writhing
test, revealing that this effect may not have a relationship with the opioid systems. Concluding, this report
highlights harmicine as a new candidate to be used as analgesic in the future. Therefore, further studies are
being undertaken in order to understand the exact mechanisms involved with the antinociceptive properties
of harmicine.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The β-Carboline type alkaloids were ﬁrst isolated from Peganum
harmala species (Zygophillaceae, Syrian Rue). Throughout the last
two decades, numerous β-carbolines alkaloids have been isolated
and identiﬁed as major active compounds presented in many plant
species and marine invertebrates such as tunicates, sea squirts, and
sponges. Additionally, several β-carboline alkaloids such as harman,
harmine, harmaline, harmalan and other tetrahydro-β-carbolines
are distributed in several different tissues and ﬂuids from a variety
of mammals (Cao et al., 2007).
These alkaloids exhibit a wide spectrum of pharmacological activi-
ties, including antispasmodic, antipyretic, anticancer, actions on the
central nervous system such as hallucinogenic properties with central
inhibition of monoamine oxidase, inhibition of platelet aggregation,
and immunomodulatory effects (Farouk et al., 2008). According to
Miralles et al. (2005) several β-carbolines have shown to display high+55 19 21392852.
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ier OA license.afﬁnity and selectivity for imidazole receptors I1, I2 and/or I3. Also,
such ligands as imidazole and some β-carbolines share the ability to in-
teract with the opioid system in the CNS reducing tolerance to opioid
drugs and increasing the analgesia afforded bymorphine on supraspinal
region in rodents.
Considering the wide spectrum of pharmacological activities attrib-
uted to theβ-carboline alkaloids and their potential for interactionwith
the central and peripheral nervous systems, this paper describes the
antinociceptive properties of harmicine using chemical-induced noci-
ception in mice. Therefore, the aims of this paper were: i) evaluation
of the antinociceptive properties of harmicine and ii) evaluation of
some mechanisms of modulation that harmicine may act through. The
ﬁndings of the present work were obtained evaluating the antinocicep-
tive properties of harmicine on the writhing, formalin, glutamate, and
capsaicin tests.
2. Materials and methods
2.1. Synthesis of (+/−)-harmicine
The synthesis of (+)-harmicine was recently described by da Silva et
al. (2009) as a novel asymmetric reduction involving a supramolecular
palladium catalyst. This same approach was employed in this work to
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the reducing agent. According to this procedure, tryptaminewas straight-
forwardly converted to the corresponding amide after reacting with suc-
cinic anhydride which underwent Bischler–Napieralsky cyclization after
the conversion to the corresponding ethyl ester. Reduction with sodium
borohydride afforded harmicine after reduction of the lactam with alane
in 5 steps and 62% overall yield from tryptamine (Fig. 1). The compound
was characterized by comparison with spectral data (IR, EIMS, 1H and
13C NMR) previously reported (da Silva et al. 2009).
2.2. Animals
Male Swiss mice with 25–35 g body weight were kept at 25±2 °C
in 12 h light–dark cycles (light phase started at 7:00 am) maintained
(10 animals per cage) with water and food ad libitum, for at least
7 days prior to assays. Separate groups of mice were used for each an-
algesic test, and the animals were used only once in the experiments.
Studies were carried out in accordance with the Current Guidelines
for the Veterinary Care of Laboratory Animals—Joint Working Group
on Veterinary Care, Finland (Voipio et al., 2008) and were performed
under the consent and surveillance of the Institute of Biology Ethics
Committee for Animal Research (2127-1), University of Campinas.
The number of animals and the intensity of the noxious stimuli
were the minimum necessary to obtain reliable data.
2.3. Drugs
All drugs were diluted in a vehicle made of 1% Tween80 (Sigma-
Aldrich, U.S.A) in 0.9% saline solution (NaCl diluted in distilled water),
considering each different chemical characteristics (hydrophilic/lipo-
philic). Reagents were diluted in phosphate buffer solution (PBS, pH
6.8). The drugs pentobarbital (Cristália—Brazil), dexamethasone, nalox-
one hydrochloride (Sigma-Aldrich, U.S.A.), morphine hydrochloride
(Johnson & Johnson, Brazil) and the following reagents—acetic acid,
formaldehyde, capsaicin, and glutamic acid from Sigma-Aldrich, U.S.A—
were used.
2.4. Evaluation of locomotor activity
The ambulatory behavior was assessed in an open ﬁeld as described
previously (Spindola, 2010) with changes on the experimental time.
The apparatus consisted of a plastic box measuring 45×45×20 cm,Fig. 1. Chemical structure of the β-with the ﬂoor divided into 9 equal squares (15×15 cm). The number
of squares crossed with all paws (crossing) was counted in a 6-min ses-
sion for each animal group (n=6), and considered indicative for the
quantiﬁcation of the locomotor activity. For this purpose, mice were
treated intraperitoneally (i.p.) with harmicine (1, 3, 10 and 30 mg/kg),
pentobarbital (35 mg/kg), or vehicle 30 min beforehand.2.5. Writhing test
The test was performed as described previously by Spindola et al.
(2010). Groups of mice (n=6) were treated i.p with vehicle (10 ml/
kg) and harmicine using four doses 1, 3, 10, and 30 mg/kg (i.p.).
Writhings were induced by an i.p. injection of 0.8% acetic acid solu-
tion (10 ml/kg), 30 min after treatment. After this injection, the num-
bers of writhings (abdominal constrictions) were cumulatively
counted over 15 min, for nociception evaluation. Also, in order to
evaluate the participation of the opioid system in the antinociceptive
properties of harmicine in the same test, different groups of mice
were pre-treated with naloxone hydrochloride (opioid antagonist—
1 mg/kg, i.p.) or vehicle (10 ml/kg), and after 20 min they then re-
ceived morphine (20 mg/kg, i.p.), harmicine (1 mg/kg, i.p.) or vehicle,
30 min prior to acetic acid injection. Data represent the average of the
total writhing observed per dose concentration.2.6. Formalin test
The formalin test was carried out as described by Woolfe and
Macdonald (1944) with few changes in the protocol. Formalin-induced
pain behavior is biphasic: the initial acute phase (0–5 min, neurogenic
pain) is followed by a relatively short quiescent period, which is then fol-
lowed by a prolonged tonic response (25–40 min, inﬂammatory pain).
Groups ofmice (n=6)were treated i.p. with: vehicle (10ml/kg, negative
control), the positive control for the neurogenic phasemorphine (20 mg/
kg, determined previously), the positive control for the inﬂammatory
phase dexamethasone (10 mg/kg, determined previously), and the
dose–response of harmicine (1, 3, 10 and 30 mg/kg). After 30 min, ani-
mals were injected with 20 μl of a formalin solution (formaldehyde
1.2%, in PBS) into the plantar surface of the right hind paw. The total
time spent by animal licking or biting the injected paw, an index of noci-
ception, was recorded for the following 40 min.carboline derivative harmicine.
Fig. 2. Abdominal constrictions induced by acetic acid (0.8% in saline) in mice previous-
ly administered (30 min) i.p. with control vehicle (10 ml/kg) or harmicine (1, 3, 10,
30 mg/kg). Results expressed as mean±S.E.M. of up to 8 animals for experimental
groups (**Pb0.01; ***Pb0.001).
Fig. 3. Effect of pre-treatment of animals with naloxone hydrochloride (1 mg/kg, i.p.)
on the antinociceptive proﬁle of harmicine (1 mg/kg, i.p.), against the acetic acid-
induced writhing in mice. Each column represents the mean of 6 to 8 animals and
the error bar indicates the S.E.M. **Pb0.01, ***Pb0.001 compared to corresponding
control values (injected with vehicle only); #P≤0.05 compared to the agonist group
(reversing effect).
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As described by our group (Spindola et al., 2010), different groups
of animals (n=6) were treated i.p. with vehicle (10 ml/kg) and with
harmicine in a dose–response manner (1, 3, 10, and 30 mg/kg). After
30 min, 40 μl of capsaicin (1.6 μg/paw prepared in PBS) was injected
in the ventral surface of the right hind paw. The time that the animals
spent licking the injected paw, for the ﬁrst 5 min post capsaicin injec-
tion, was recorded with a chronometer and considered as indicative
of nociception.
2.8. Glutamate test
This test was performed to elucidate the possible participation of pe-
ripherally glutamatergic system as described previously (Spindola et al.,
2010), with no use of positive control. Different groups of animals
(n=6) were treated i.p. with harmicine in a dose-related manner (1,
3, 10 and 30 mg/kg). 30 min after treatments, 20 μl of glutamate solu-
tion (glutamic acid in PBS) was injected in the ventral surface of the
right hind paw (10 μmol/paw), and was observed individually for
15 min. The amount of time spent licking the injected pawwas chrono-
metered and considered as indicative of nociception.
2.9. Statistical analysis
All results were submitted to one way analysis of variance
(ANOVA), considering as critical level pb0.05 to evaluate signiﬁcant
difference between the control and treated groups, followed by Dun-
can’s Test, using Stat Soft® software. Graphs were designed using the
Origin® software.
3. Results
3.1. Evaluation of locomotor activity
On a preliminary set of experiments in our laboratory, animals
treated with 30 mg/kg doses of harmicine did not demonstrate acute
toxicity signals, therefore this dose was chosen as the highest one to
be tested on antinociceptive assays. Therefore, the dose–response
curves designed for the i.p. treatment with harmicine in the following
assays were determinedwith the logarithmic scale 1, 3, 10 and 30 mg/
kg. For locomotor activity in the open-ﬁeld test, the number of cross-
ing observed for control groups was: vehicle 70.5±15 (10 ml/kg,
i.p.); pentobarbital *36±11 (35 mg/kg, i.p.). The dose–response treat-
ment with harmicine (1, 3, 10 and 30 mg/kg, i.p.) produced 79±13;
61±8; 53±10; and ***14±3 crossing respectively. Results expressed
as mean±S.E.M. of up to 6 animals (*Pb0.05 and ***Pb0.001). These
results indicated that the dose of 30 mg/kg produced either depressive
central activity, or relaxant effects, leading to misinterpretation with
behavioral antinociceptive experimental models.
3.2. Writhing test
The dose–response observed in Fig. 2 showed that harmicine (1, 3,
10 and 30 mg/kg, i.p.) in the writhing test produced a signiﬁcantly
antinociception effect reducing writhings in mice (60%, 48%, 52%,
and 75%) compared to the control group (vehicle only) (**Pb0.01;
***Pb0.001).
The results presented in Fig. 3 demonstrated that harmicine
(1 mg/kg, i.p.) and the opioid agonist morphine (20 mg/kg, i.p.) pro-
duced signiﬁcant antinociception which was conﬁrmed by the reduc-
tion of writhings in mice (57% and 78%), compared to the control
group (vehicle only). The pre-treatment with the opioid antagonist
naloxone hydrochloride (1 mg/kg, i.p.), signiﬁcantly reversed the
antinociception caused by morphine, however not by harmicine(69%), suggesting that this compound does not act by this system,
on this test (**Pb0.01, ***Pb0.001).
3.3. Formalin test
Results presented in Fig. 4 showed that in the ﬁrst phase of formalin
test (0–5 min), morphine (20 mg/kg, i.p.) and harmicine (1, 3, 10 and
30 mg/kg, i.p.) produced a signiﬁcantly antinociception reducing reaction
time in mice, compared to the control group (45%, 60%, 75%, 78%, and
100%). Dexamethasone (10 mg/kg, i.p.) did not show activity during
this phase (*Pb0.05; **Pb0.01; ***Pb0.001). Results presented in Fig. 5
showed that on the second phase of formalin test (25–40 min),morphine
(20 mg/kg, i.p.), dexamethasone (10 mg/kg, i.p.), and harmicine (10 and
30 mg/kg, i.p.) produced a signiﬁcant antinociceptive effect, reducing re-
action time of mice (59%, 53%, 68%, and 100%) compared to the control
group (vehicle only, i.p.). These results demonstrated the effectiveness
of harmicine better against neurogenic pain than to inﬂammatory pain
(*Pb0.05; ***Pb0.001).
Fig. 4. First phase (0–5 min) for reactivity time to the intraplantar application of forma-
lin (formaldehyde 1.2% in PBS) in the hind paw of mice previously treated i.p. (30 min.)
with control vehicle (10 ml/kg), morphine (20 mg/kg), dexamethasone (10 mg/kg), or
harmicine (1, 3, 10, 30 mg/kg). Results expressed as mean±S.E.M. of up to 6 animals
for experimental groups (*Pb0.05; **Pb0.01; ***Pb0.001).
Fig. 6. Reactivity time to the intraplantar application of capsaicin (1.6 μg/paw) in the
hind paw of mice previously treated (30 min.) i.p. with control vehicle (10 ml/kg), or
harmicine (1, 3, 10, 30 mg/kg). Results expressed as mean±S.E.M. of up to 6 animals
for experimental groups (*Pb0.05; ***Pb0.001).
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In the evaluation of the peripherally vanilloid receptors, Fig. 6 showed
that in the capsaicin test, harmicine (1, 3, 10 and 30 mg/kg, i.p.) produced
a signiﬁcant antinociception effect (*Pb0.05; ***Pb0.001) reducing the
mice reaction time around 11%, 41%, 84%, and 90% respectively, compared
to the control group (vehicle only).3.5. Glutamate test
Evaluating the possible participation of the peripheral glutamatergic
system with the glutamate test (Fig. 7), harmicine (1, 3, 10 and 30 mg/
kg, i.p.) produced a signiﬁcant antinociceptive effect (*Pb0.05;
***Pb0.001) reducing the reaction time of the mice around 50%, 97%,
86%, and 100% respectively, compared to the control group (vehicle only).Fig. 5. Second phase (25–40 min) for reactivity time to the intraplantar application of
formalin (formaldehyde 1.2% in PBS) in the hind paw of mice previously treated
(30 min.) i.p. with control vehicle (10 ml/kg), morphine (20 mg/kg), dexamethasone
(10 mg/kg), or harmicine (1, 3, 10, 30 mg/kg). Results expressed as mean±S.E.M. of
up to 6 animals for experimental groups (*Pb0.05; ***Pb0.001).4. Discussion
Among the many lead compounds identiﬁed from natural products,
β-carbolines have been described with antidepressant effects related to
their binding to benzodiazepine, imidazoline, serotonin, and opiate re-
ceptors as well as MAO inhibition. Antidepressants have been postulat-
ed to modulate pain through the central and peripheral nervous
systems. Effects on peripheral nociceptors, descending inhibitory pain
pathways, central sensitization and brain areas involved in pain and
emotional processing have also been described, providing an effective
option in the treatment of some pain conditions (Herraiz et al., 2007).
Previous ﬁndings on the biological properties of the β-carboline clas-
ses permitted to explore the antinociceptive properties of harmicine,
based on chemical behavioral in vivo bioassays. Results presented herein
provided consistent data to support the potential use of harmicine as a
future analgesic. The most relevant ﬁndings of the present work were
that harmicine administered intraperitoneally (i.p.) in mice: i) produced
a signiﬁcantly antinociceptive effect in the writhing test; ii) did notFig. 7. Reactivity time to the intraplantar application of glutamate (10 μmol/paw) in the
hind paw of mice previously treated (30 min.) i.p. with control vehicle (10 ml/kg), or har-
micine (1, 3, 10, 30 mg/kg). Results expressed as mean±S.E.M. of up to 6 animals for ex-
perimental groups (*Pb0.05; ***Pb0.001).
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strated higher effectiveness to neurogenic pain, as revealed by the forma-
lin test; iv) seemed to act peripherally via vanilloid receptors as revealed
by the capsaicin test; and v) seemed to act via peripheral ionotropic and/
or metabotropic glutamate receptors, as revealed by the glutamate test.
The locomotor activity is generally believed to be a result from
brain activation, which is manifested as an excitation of central neu-
rons and an increase in cerebral metabolism (Calabresi et al., 2000).
The present study showed that i.p. treatment with harmicine had
no effects on motor coordination, as reﬂected by open-ﬁeld test, at
doses providing threshold antinociceptive activity in all animal
models studied. However, i.p. harmicine at the highest dose used
(30 mg/kg) affected motor coordination, as a consequence of seda-
tion, hallucination, anxiety or fear (Prut and Belzung, 2003).
Acetic-acid induced pain (writhing test) is a screening tool for the
assessment of analgesic or anti-inﬂammatory properties of natural or
synthetic compounds. The acid acts indirectly by inducing the release
of endogenous mediators, which stimulate the nociceptive neurons.
Inﬂammatory pain transmission primarily involves peripheral poly-
modal receptors around small vessels which signal to the CNS via sen-
sory afferent C-ﬁbers entering the dorsal horn. However this chemical
method has good sensitivity but poor speciﬁcity allowing misinter-
pretation of the results, because this is an unspeciﬁc stimulus for
nociception, sensible to drugs with different mechanisms. This prob-
lem can be avoided by complementation with other nociception
models, as described herein (Collier, 1968; Kumazawa, 1996). Our re-
sults showed that harmicine did not signiﬁcantly interfere with
motor performance at doses that suppressed the writhing response,
suggesting the potential use for pain relief.
Moreover, this work also evaluated the possible involvement of
the opioidergic system in the antinociception effects of harmicine in
the same model. The opioid system modulates several physiological
processes, including analgesia, stress response, and neuroendocrine
function. The analgesic effect is mainly due to the actions of morphine
on μ opioid receptors in dorsal root ganglion and in the dorsal horn to
inhibit nerve ﬁbers that signal pain to the brain (Kieffer, 1995). The
antinociceptive effect of harmicine possibly related to opioid recep-
tors, was evaluated by using the opioid antagonist naloxone hydro-
chloride prior to the treatment of animals with the compound, in
order to observe partial or total reversing effects. The antinociceptive
activity of harmicine was not signiﬁcantly antagonized by naloxone,
suggesting that opioidergic mechanisms were not involved in the ex-
pression of the antinociceptive effect of harmicine, in this assay.
Neurogenic pain is caused by the direct activation of nociceptive
nerve terminals, whereas inﬂammatory pain is mediated by a combina-
tion of peripheral input and spinal cord sensitization. Formalin produces
signiﬁcant increases in spinal levels of different mediators related to
both neurogenic (amino acids, kinins) and inﬂammatory pathways
(prostaglandins, leukotrienes) (Santos et al., 2005). Harmicine signiﬁ-
cantly reduced both phases of the formalin test demonstrating
higher activity against neurogenic (phase I) than to inﬂammatory pain
(phase II) mediation, revealed by the signiﬁcant decreasing on reaction
time of the mice with lower doses of the compound in the phase I.
These results prompted us to explore the harmicine’s peripheral antino-
ciceptive activity via vanilloid and glutamatergic systems, since these re-
ceptors are involved in the sensitization of several pain disorders, and are
considered important targets for pain control (Santos and Calixto, 1997).
The peripherally use of capsaicin (the pungent substance of Capsi-
cum peppers) serves as a molecular integrator of noxious chemical
stimuli, releasing neuropeptides, excitatory amino acids (glutamate
and aspartate), nitric oxide and pro-inﬂammatory mediators in the
periphery, transmitting nociceptive information to the spinal cord.
Harmicine signiﬁcantly reduced the neurogenic nociception caused
by the intraplantar injection of capsaicin in a dose-dependent man-
ner, as in the ﬁrst phase of the formalin test (neurogenic response).
One important mechanism underlying these phenomena is themodulation (sensitization) of ion channels sensible to capsaicin
such as the vanilloid TRPV1 (Szallasi et al., 1993; Caterina and Julius,
2001), indicating that, at least in part, harmicine seemed to act via
vanilloid system.
Glutamate is the predominant excitatory neurotransmitter of the
central and peripheral nervous system being released at various levels
of the nociceptive pathways in response to inﬂammation or tissue injury
(Yashpal et al., 2001). Our results also showed that i.p. administration of
harmicine produced a signiﬁcant inhibition of the nociceptive response
caused by intraplantar injection of glutamate into the mouse hindpaw,
suggesting that the compound might act via glutamatergic system. In
fact, the intraplantar injection of glutamate induces direct stimulation of
nociceptive neurons, releasing various inﬂammatory and neuropeptides
involved in the transmission of pain, mediated via ligand gated inotropic
glutamate (iGlu) receptors and G-protein coupled metabotropic gluta-
mate (mGlu) receptors, corroborating the effectiveness of harmicine
against neurogenic pain stimuli observed in the formalin and capsaicin
tests. Compounds with these actions are good candidates for treatment
of neuropathic pain (Bordi and Ugolini, 1999).
Together, all these results highlighted harmicine as a novel impor-
tant candidate for clinical use on pain relief, demonstrated by the efﬁca-
cy on different pain states. Further studies are being undertaken in
order to better understand the harmicine antinociceptive mechanisms
of action.
5. Conclusion
The racemic form of (+/−) harmicine demonstrated activity
against chemical experimental models of pain, suggesting the poten-
tial use for different pain disorders. The present work demonstrated
that harmicine administered intraperitoneally in mice: i) produces a
signiﬁcantly antinociceptive activity on the writhing test, and this ef-
fect does not seem to be via the opioid system; ii) demonstrate effec-
tiveness toward neurogenic pain, possibly involved with nociceptive
terminals and/or peripheral input and spinal cord sensitization, as
revealed by formalin test; iii) seems to act via vanilloid systems, as
revealed by capsaicin test; iv) seems to act via peripheral glutamate
systems, as revealed by glutamate test.
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